AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22423114 — intervention group
Group type: COMPARATOR
Intervention: Univariate adaptation-fMRI paradigm
Number of subjects: 0
Study 15953498 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day)
Number of subjects: 38
Study 15953498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12426230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg loading dose and 10 mg/hour until Day 3)
Number of subjects: 40
Study 12426230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40
Study 12426230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone withdrawal
Number of subjects: 40
Study 12426230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9514066 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Before
Number of subjects: 128
Study 9514066 — intervention group
Group type: COMPARATOR
Intervention: Video After
Number of subjects: 128
Study 7708993 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 35
Study 7708993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2651508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2651508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 782804 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 0
Study 782804 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily before surgery
Number of subjects: 118
Study 31405764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 28057360 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 837
Study 28057360 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47)
Number of subjects: 837
Study 26174611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0837 (oral direct thrombin inhibitor)
Number of subjects: 601
Study 26174611 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 601
Study 23428337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (2.5, 10, or 60 mg)
Number of subjects: 11
Study 23428337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (30 mg)
Number of subjects: 11
Study 21526919 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine upfront abciximab administration (bolus followed by 12-hour infusion)
Number of subjects: 80
Study 21526919 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (selective abciximab use during intervention)
Number of subjects: 80
Study 21526919 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine upfront abciximab administration
Number of subjects: 80
Study 21526919 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 80
Study 17962243 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 99
Study 17962243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 99
Study 17962243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 17962243 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS
Number of subjects: 99
Study 16243440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 300 mg/m2
Number of subjects: 132
Study 16243440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12527537 — intervention group
Group type: COMPARATOR
Intervention: Standard Cognitive-Behavior Therapy (CBT)
Number of subjects: 0
Study 12527537 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Cognitive-Behavior Therapy (ECBT)
Number of subjects: 0
Study 12527537 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 10638560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (PANT) 40 mg
Number of subjects: 222
Study 10638560 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (RAN) 300 mg
Number of subjects: 222
Study 8785033 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide membrane hemodialysis for 4 months
Number of subjects: 6
Study 1548988 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright water-based exercise at 60% of maximal treadmill heart rate
Number of subjects: 10
Study 1548988 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright water-based exercise at 70% of maximal treadmill heart rate
Number of subjects: 10
Study 10272531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard/telephone reminder system
Number of subjects: 102
Study 30231915 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Acute Stroke Intervention (EASI)
Number of subjects: 0
Study 30231915 — intervention group
Group type: COMPARATOR
Intervention: Thrombectomy trials (comparison)
Number of subjects: 0
Study 27894358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback-assisted, technology-supported mindfulness training (N-tsMT)
Number of subjects: 26
Study 27894358 — intervention group
Group type: COMPARATOR
Intervention: Daily online math training (control condition)
Number of subjects: 26
Study 24625519 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC line inserted through the axillary vein
Number of subjects: 62
Study 24625519 — intervention group
Group type: COMPARATOR
Intervention: PICC line inserted through other sites
Number of subjects: 62
Study 21420840 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (HF): 37% carbohydrate, 52% fat
Number of subjects: 10
Study 21420840 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat meal (MF): 61% carbohydrate, 27% fat
Number of subjects: 10
Study 21422713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d) and Vitamin C (500 mg/d) supplementation
Number of subjects: 40
Study 21422713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 18695096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine eyedrops for 6 months
Number of subjects: 419
Study 18695096 — intervention group
Group type: COMPARATOR
Intervention: Patching for 6 months
Number of subjects: 419
Study 15871318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured keratinocytes
Number of subjects: 4
Study 15871318 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gauze (control)
Number of subjects: 4
Study 12135218 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy and endometrial biopsy
Number of subjects: 370
Study 12135218 — intervention group
Group type: COMPARATOR
Intervention: Endometrial biopsy alone
Number of subjects: 370
Study 12135218 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Number of subjects: 370
Study 10539870 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d Zithromax for 3 days then 600 mg/wk for 11 additional weeks
Number of subjects: 3500
Study 10539870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study 8580577 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-peptide enteral diet
Number of subjects: 41
Study 8580577 — intervention group
Group type: COMPARATOR
Intervention: Whole-protein diet
Number of subjects: 41
Study 2317751 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous combined technique therapy (SIM)
Number of subjects: 48
Study 2317751 — intervention group
Group type: COMPARATOR
Intervention: Sequential combined technique therapy (SEQ)
Number of subjects: 48
Study 30526388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia bark extract tablets
Number of subjects: 66
Study 30526388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 1105
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP usage >4 h·night−1
Number of subjects: 1105
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: Good CPAP adherence with ESS >10 at baseline
Number of subjects: 1105
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower average nightly CPAP use
Number of subjects: 1105
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sleepiness at baseline
Number of subjects: 1105
Study 25599884 — intervention group
Group type: EXPERIMENTAL
Intervention: Boomerang™ wire with manual compression (MC)
Number of subjects: 450
Study 25599884 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC) alone
Number of subjects: 450
Study 24862623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS group)
Number of subjects: 408
Study 24862623 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS group)
Number of subjects: 408
Study 22622962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (choline fenofibrate) 135 mg once daily
Number of subjects: 682
Study 22622962 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atorvastatin treatment
Number of subjects: 682
Study 19258485 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 0
Study 19258485 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions with behavioral components
Number of subjects: 0
Study 19258485 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions with behavioral and/or cognitive components
Number of subjects: 0
Study 19258485 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17566199 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential-pressure valves
Number of subjects: 737
Study 17566199 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta valves
Number of subjects: 737
Study 17566199 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbis-Sigma valves
Number of subjects: 737
Study 17566199 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at shunt insertion (42 days) compared to older age (134 days)
Number of subjects: 737
Study 17566199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus secondary to infection, head injury, or aqueductal stenosis
Number of subjects: 737
Study 15863647 — intervention group
Group type: COMPARATOR
Intervention: Serum TIMP-1 concentration in stable COPD patients
Number of subjects: 72
Study 15863647 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TIMP-1 concentration during disease exacerbation in COPD patients
Number of subjects: 72
Study 15863647 — intervention group
Group type: COMPARATOR
Intervention: Molar ratio of MMP-9 to TIMP-1 in COPD patients
Number of subjects: 72
Study 15863647 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum TIMP-1 concentration with forced expiratory volume in one second/forced vital capacity in COPD patients
Number of subjects: 72
Study 14964594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies
Number of subjects: 0
Study 9285657 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillators (ICDs)
Number of subjects: 1117
Study 9285657 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (amiodarone or sotalol)
Number of subjects: 1117
Study 9285657 — intervention group
Group type: COMPARATOR
Intervention: Registry patients (nonrandomized)
Number of subjects: 1117
Study 8174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 180
Study 8174890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 3453292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride 80 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 30
Study 3453292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30144304 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BD) 256 μg
Number of subjects: 100
Study 30144304 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (MNT) 10 mg
Number of subjects: 100
Study 30144304 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose Budesonide (hBD) 128 μg + Montelukast (MNT)
Number of subjects: 100
Study 26523526 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 28
Study 26523526 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 28
Study 26523526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 28
Study 25526439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 20 mg/kg/day for 2 years, then escalated to 30 mg/kg/day during extension study.
Number of subjects: 28
Study 25526439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 30 mg/kg/day, then decreased to 26 mg/kg/day (range 19.5-31.2).
Number of subjects: 28
Study 25526439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy.
Number of subjects: 28
Study 22652314 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Balloon Angioplasty (PTA)
Number of subjects: 40
Study 22652314 — intervention group
Group type: COMPARATOR
Intervention: Cryoplasty (CRYO)
Number of subjects: 40
Study 20527138 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion extract cream with Centella asiatica and hyaluronic acid applied twice daily for 12 weeks
Number of subjects: 0
Study 20527138 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control) applied to the contralateral side
Number of subjects: 0
Study 18538305 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias training (Group T) for 7 days using the dot‐probe paradigm
Number of subjects: 0
Study 18538305 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study 18538305 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias training (Group T)
Number of subjects: 0
Study 16043680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/d or 800 IU for 2 years, then increased to 50 microg/d or 2000 IU for 1 additional year)
Number of subjects: 208
Study 16043680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 15228673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF 75 micro g per day s.c. for 5 ‐ 7 days, additional 3 ‐ 5 days according to leukopenia during radiotherapy
Number of subjects: 100
Study 15228673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhG‐CSF)
Number of subjects: 100
Study 10685532 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 100
Study 10685532 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 100
Study 9113582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bupivacaine hydrochloride plus 0.1 mL subconjunctival lignocaine
Number of subjects: 50
Study 9113582 — intervention group
Group type: COMPARATOR
Intervention: Standard peribulbar anesthesia
Number of subjects: 50
Study 8402801 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium lactate
Number of subjects: 60
Study 8402801 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium lactate plus sodium lauryl sulphate
Number of subjects: 60
Study 8402801 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 60
Study 3519191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with the rigid Negus oesophagoscope using general anaesthesia
Number of subjects: 0
Study 3519191 — intervention group
Group type: COMPARATOR
Intervention: Combined paravariceal and intravariceal sclerotherapy technique using a fibreoptic endoscope without anaesthesia
Number of subjects: 0
Study 3257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day
Number of subjects: 35
Study 3257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 10 days
Number of subjects: 35
Study 3257288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 28 days
Number of subjects: 35
Study 3257288 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 35
Study 31777949 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg UPA per day for 5 days
Number of subjects: 25
Study 31777949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31857893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fibre refined diet
Number of subjects: 0
Study 31857893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet with intact cellular structures
Number of subjects: 0
Study 31857893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet with disrupted cellular structures
Number of subjects: 0
Study 31857893 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28335012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for working memory improvement (4 sessions of 1 hour each)
Number of subjects: 27
Study 28335012 — intervention group
Group type: COMPARATOR
Intervention: Active control group (no hypnotic suggestion)
Number of subjects: 27
Study 28335012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for working memory improvement
Number of subjects: 27
Study 25975871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T380
Number of subjects: 120
Study 25975871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload 375
Number of subjects: 120
Study 25975871 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-T380A
Number of subjects: 120
Study 24042991 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad compression massage (BCM)
Number of subjects: 40
Study 24042991 — intervention group
Group type: COMPARATOR
Intervention: Light contact touch (LCT)
Number of subjects: 40
Study 21640056 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training - PFMT) delivered by a specialist continence physiotherapist or nurse
Number of subjects: 853
Study 21640056 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 853
Study 21640056 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conservative treatment (PFMT)
Number of subjects: 853
Study 19537306 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine fortified with 200 microg folic acid/10 g portion (centre M)
Number of subjects: 126
Study 19537306 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the consumption of vegetables to three servings per day (centre V)
Number of subjects: 126
Study 19537306 — intervention group
Group type: COMPARATOR
Intervention: Control group (centre C)
Number of subjects: 126
Study 16280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed verbal instructions and written text about postoperative course
Number of subjects: 92
Study 16280233 — intervention group
Group type: COMPARATOR
Intervention: Written text with basic oral explanations (Control)
Number of subjects: 92
Study 14756716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg) + lower intensity counseling
Number of subjects: 1524
Study 14756716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg) + higher intensity counseling
Number of subjects: 1524
Study 14756716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg) + lower intensity counseling
Number of subjects: 1524
Study 14756716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg) + higher intensity counseling
Number of subjects: 1524
Study 11425939 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl treatment
Number of subjects: 800
Study 11425939 — intervention group
Group type: COMPARATOR
Intervention: Tocopherol treatment
Number of subjects: 800
Study 11425939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 11425939 — intervention group
Group type: COMPARATOR
Intervention: Combination of deprenyl and tocopherol
Number of subjects: 800
Study 9262882 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 mg/kg PPA
Number of subjects: 20
Study 9262882 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.66 mg/kg PPA
Number of subjects: 20
Study 9262882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg PSE
Number of subjects: 20
Study 9262882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg PSE
Number of subjects: 20
Study 9262882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8334179 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g protein/kg/day (high N diet)
Number of subjects: 15
Study 8334179 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g protein/kg/day (low N diet)
Number of subjects: 15
Study 8334179 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous pilot study with 20 similar patients
Number of subjects: 15
Study 3549902 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized donor and recipient pretransplant with tetanus toxoid (TT)
Number of subjects: 28
Study 3549902 — intervention group
Group type: COMPARATOR
Intervention: T cell-depleted marrow transplantation
Number of subjects: 28
Study 3549902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with TT at 3, 6, and 12 months posttransplant
Number of subjects: 28
Study 3549902 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized donor and/or recipient pretransplant
Number of subjects: 28
Study 29992824 — intervention group
Group type: EXPERIMENTAL
Intervention: Information technology-based 2-way referral
Number of subjects: 0
Study 29992824 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 community health centers)
Number of subjects: 0
Study 26909844 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 27
Study 26909844 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 27
Study 24607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 41 weeks' gestation and beyond
Number of subjects: 0